PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1987687-1 1991 Serum interleukin 6 (IL-6) levels were utilized as an immunologic marker of activation of T cells and macrophages in renal allograft recipients treated with a cyclosporine and prednisone immunosuppressive regimen. Prednisone 176-186 interleukin 6 Homo sapiens 21-25 7530507-4 1995 We have analyzed the prognostic significance of serum immunoreactive IL-6, as measured by a sensitive immunosorbent assay, in 210 patients with newly diagnosed MM subsequently treated with intermittent melphalan and prednisone. Prednisone 216-226 interleukin 6 Homo sapiens 69-73 8106631-12 1994 Treatment of 2 such patients with prednisone was associated with a dramatic reduction and prompt normalization of IL-6 and thyroid hormone values. Prednisone 34-44 interleukin 6 Homo sapiens 114-118 16708557-0 2005 [The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone]. Prednisone 116-126 interleukin 6 Homo sapiens 18-22 16708557-5 2005 The aim of the present study was to examine the influence of - 174 interleukin-6 (IL-6) promoter polymorphism on the efficacy of treatment of RA patients with methotrexate and prednisone. Prednisone 176-186 interleukin 6 Homo sapiens 67-80 16708557-5 2005 The aim of the present study was to examine the influence of - 174 interleukin-6 (IL-6) promoter polymorphism on the efficacy of treatment of RA patients with methotrexate and prednisone. Prednisone 176-186 interleukin 6 Homo sapiens 82-86 15696567-8 2005 After 4 weeks of prednisone therapy, ESR was elevated in 13.2% patients, CRP in 41.9%, and serum IL-6 in 37.2%. Prednisone 17-27 interleukin 6 Homo sapiens 97-101 12672196-6 2003 Normal ESR, CRP, and IL-6 levels persisted after the suspension of infliximab and prednisone during the followup period, paralleling the clinical remission. Prednisone 82-92 interleukin 6 Homo sapiens 21-25 8768854-9 1996 Exacerbation of thyrotoxicosis with markedly increased IL-6 was controlled by prednisone in 3 of 4 cases. Prednisone 78-88 interleukin 6 Homo sapiens 55-59 29600943-11 2018 Daily prednisone dose had an inverse association with lower serum IL-4, IL6, IL-17A, IL-17E, IL-22 and IL-23. Prednisone 6-16 interleukin 6 Homo sapiens 72-75 31531960-0 2019 Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis. Prednisone 94-104 interleukin 6 Homo sapiens 12-25 35043219-5 2022 Importantly, the levels of salivary IL-6, IL-10, IFN-gamma, and TNF-alpha in RAS patients were significantly decreased following prednisone treatment (all P < 0.001). Prednisone 129-139 interleukin 6 Homo sapiens 36-40 31142476-0 2020 Analysis of IL-6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone. Prednisone 118-128 interleukin 6 Homo sapiens 12-16 34834246-6 2021 Low-dose MR prednisone seems to be able to improve the course of RA, reduce morning stiffness and morning serum levels of IL-6, and induce significant clinical benefits. Prednisone 12-22 interleukin 6 Homo sapiens 122-126 31531960-8 2019 CONCLUSION: Our study suggests that elevated levels of IL-6 in new GCA are better suppressed by MR prednisone compared with IR prednisolone. Prednisone 99-109 interleukin 6 Homo sapiens 55-59 28035387-13 2017 In conclusion, prednisone, ibuprofen and betamethasone may prevent OA by suppressing the expression of IL-6 and IL-8, subsequently inactivating NF-kappaB and STAT3 pathways, and ultimately, leading to decreased levels of collagen I, MMP-1, and MMP-13. Prednisone 15-25 interleukin 6 Homo sapiens 103-107 28035387-10 2017 Additionally, levels of IL-6 and IL-8 were significantly decreased by prednisone, ibuprofen and betamethasone. Prednisone 70-80 interleukin 6 Homo sapiens 24-28 31165299-12 2019 The anti-IL-6 receptor tocilizumab was, therefore, administered with a rapid improvement of her active psoriatic arthritis that remained dependent on low prednisone dosage. Prednisone 154-164 interleukin 6 Homo sapiens 9-13 28035387-12 2017 In combination with IL-6 or IL-8, prednisone, ibuprofen and betamethasone significantly reduced the levels of collagen I, MMP-1 and MMP-13, and inactivated NF-kappaB and STAT3 pathways. Prednisone 34-44 interleukin 6 Homo sapiens 20-24 25227591-5 2015 Circadian use of low-dose, long-term prednisone, by using night-release formulations (ingested at 10 to 11 p.m.) especially in early RA patients, appears characterized by a significantly superior efficacy on decreasing morning stiffness and IL-6 serum levels, compared to conventional daytime immediate-release prednisone. Prednisone 37-47 interleukin 6 Homo sapiens 241-245 25611207-7 2015 A significant increment in IL-10 and a significant decrement in IL-6 (p<0.05) were also observed with prednisone both at rest and during exercise, without significant change in IL-1beta. Prednisone 105-115 interleukin 6 Homo sapiens 64-68 25227901-12 2015 [Lancet 2008;371:205-214] reported CAPRA-1, which documented that modified-release prednisone or prednisolone taken at bedtime led to lower morning stiffness and IL-6 levels compared to usual morning prednisone. Prednisone 83-93 interleukin 6 Homo sapiens 162-166 20817712-6 2011 Serum IL-6 and TNF decreased during prednisone therapy in TB-IRIS patients. Prednisone 36-46 interleukin 6 Homo sapiens 6-10 24880571-9 2014 Conversely, corticosterone, prednisone, and dexamethasone similarly inhibited cell invasion and expression of related genes, including MMP-9, VEGF, and IL-6, in GR-positive lines. Prednisone 28-38 interleukin 6 Homo sapiens 152-156 21529308-12 2011 Taken at bedtime (approximately 10:00 pm), these tablets give programmed delivery of prednisone around 4 h later, at the optimal time to suppress IL-6. Prednisone 85-95 interleukin 6 Homo sapiens 146-150 20535794-9 2010 IL-6 was significantly higher in patients still requiring prednisone (mean +/- SD 29 +/- 45 versus 13 +/- 17 pg/ml; P = 0.008), and TNFalpha correlated with cumulated prednisone dose (r = 0.292, P = 0.04). Prednisone 58-68 interleukin 6 Homo sapiens 0-4 20535794-9 2010 IL-6 was significantly higher in patients still requiring prednisone (mean +/- SD 29 +/- 45 versus 13 +/- 17 pg/ml; P = 0.008), and TNFalpha correlated with cumulated prednisone dose (r = 0.292, P = 0.04). Prednisone 167-177 interleukin 6 Homo sapiens 0-4 20206356-2 2010 The aim of this study was to test the effects of a short-course, high-dose oral prednisone on the release of interleukin-6 (IL-6) and tumour necrosis factor (TNF)-alpha from circulating monocytes and on the neointimal growth that follows bare metal stent (BMS) implantation. Prednisone 80-90 interleukin 6 Homo sapiens 109-122 20206356-2 2010 The aim of this study was to test the effects of a short-course, high-dose oral prednisone on the release of interleukin-6 (IL-6) and tumour necrosis factor (TNF)-alpha from circulating monocytes and on the neointimal growth that follows bare metal stent (BMS) implantation. Prednisone 80-90 interleukin 6 Homo sapiens 124-128 20206356-7 2010 RESULTS: Plasma concentrations of prednisone correlated inversely with IL-6 and TNF-alpha release (R2=0.45, p=0.04 and R2=0.69, p=0.005, respectively) and NF-kappaB activation from monocytes (R2=0.58, p=0.01). Prednisone 34-44 interleukin 6 Homo sapiens 71-75